First Assist: Early Cystectomy in Non–Muscle Invasive Bladder Cancer, with Matvey Tsivian, MD

Welcome back to First Assist: GU Oncology Unpacked!

In this episode of First Assist: GU Oncology Unpacked, host Taylor Goodstein, MD, welcomes Matvey Tsivian, MD, a urologic oncologist at the Medical University of South Carolina, for an in-depth discussion on the evolving role of early radical cystectomy in non–muscle invasive bladder cancer (NMIBC). As the therapeutic landscape continues to expand with new bladder-sparing agents, the conversation explores how clinicians can identify the patients who stand to benefit most from definitive surgery while avoiding unnecessary overtreatment. Goodstein and Tsivian examine how thoughtful patient selection and individualized counseling have become increasingly important in an era of growing treatment options.

The discussion centers on the clinical and pathologic features that may warrant consideration of early cystectomy, including high-grade T1 disease with additional adverse features, variant histology, lymphovascular invasion, and urothelial carcinoma involving the prostatic urethra. Tsivian explains the ongoing challenges posed by imperfect staging tools and emphasizes that the decision to pursue surgery often hinges on balancing the risk of understaging against the possibility of disease progression during bladder-sparing treatment. The conversation also highlights the importance of repeat transurethral resection in many patients, the nuanced role of variant histology in treatment planning, and why early discussions about cystectomy can help patients better understand the full spectrum of management options from the time of diagnosis.

Beyond oncologic outcomes, Goodstein and Tsivian devote considerable attention to quality-of-life considerations. They discuss how repeated intravesical therapies, surveillance procedures, treatment-related adverse effects, travel burden, and financial toxicity all contribute to the patient experience and should be weighed alongside the morbidity of radical cystectomy. Drawing on data from the CISTO trial,¹ they challenge the common perception that cystectomy results in poorer quality of life than bladder-sparing approaches, emphasizing the importance of shared decision-making based on each patient's priorities. The conversation also explores practical aspects of perioperative care, including prehabilitation, patient education, ostomy support, and the value of high-volume centers, in optimizing surgical outcomes.

Looking toward the future, the episode examines emerging biomarkers, artificial intelligence–based pathology tools, and urinary and circulating tumor DNA as potential methods for improving risk stratification in NMIBC. Although these technologies are not yet ready for routine clinical decision-making, Tsivian discusses their potential to complement traditional staging and better identify patients who would benefit from earlier intervention. As systemic therapies and bladder-preserving treatments continue to advance, he suggests that the role of radical cystectomy is likely to become more selective rather than obsolete. For trainees and practicing urologists alike, this episode provides a thoughtful examination of nuanced treatment decisions in bladder cancer care, emphasizing that successful management depends on patient-centered decision-making.

REFERENCE